Shares of Regeneron Pharmaceuticals (REGN) were down 1.70% on Apr 11, following a complaint filed by the U.S. Department of Justice against the company, alleging fraudulent drug pricing practices related to its lead drug, Eylea.The Department filed a complaint under the False Claims Act (FCA) against Regeneron, which manufactures and sells the ophthalmology drug, Eylea. The lawsuit was originally filed under the qui tam or whistleblower provisions of the FCA.Eylea is an anti-vascular endothelial growth fact ...

Key TakeawaysRegeneron shares were lower ahead of the opening bell Thursday morning after the DOJ filed a complaint accusing the drugmaker of manipulating Medicare’s drug pricing process.The DOJ Alleges the company failed to report credit card fees that it paid distributors.Regeneron shares may find support around $915 from a nine-month trendline. A breakdown below this level could see a retest of a key horizontal line near $835. Shares in biotech giant Regeneron Pharmaceuticals (REGN) go under the microsco ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

Linvoseltamab关键试验数据 - Regeneron Pharmaceuticals, Inc.宣布了linvoseltamab在复发/难治性多发性骨髓瘤（MM）患者中的关键试验数据[1] - Linvoseltamab是一种正在研究的双特异性抗体，旨在连接多发性骨髓瘤细胞上的B细胞成熟抗原（BCMA）和表达CD3的T细胞，以促进T细胞激活和杀伤癌细胞[2] - Linvoseltamab治疗导致早期、持久且随时间加深的反应，对于这些经过重度治疗的患者群体来说，这些都是关键的疗效指标[3] - Linvoseltamab数据显示，117名患者中71%的客观反应率（ORR），46%的患者达到完全缓解（CR）或更好，62%的患者达到非常好的部分缓解（VGPR）或更好[4]

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. If you own REGN please contact Justin Kuehn, Esq. by email at justin@kuehn.law or call (833) 672-0814.  The consultation and case are fr ...

业绩总结 - EYLEA在去年第四季度的净销售额达到1.23亿美元，EYLEA系列在整个市场中占据了约49%的份额[5] - 非GAAP毛利率指导在89%至91%之间，2024年的启动成本会影响毛利率[27] - 公司在投资这些项目时会进行严格的流程，根据多种因素来平衡资本投资[32] 用户数据 - 近期已经发货超过10万份EYLEA HD订单，这对于医生来说是一个重要的里程碑，有助于提高对产品安全性的信心[6] - 大部分转换来自EYLEA 2毫克到HD，但也有来自其他品牌药物和Avastin的转换，以及逐渐增长的新患者[7] - 96周数据支持了EYLEA HD的临床特性，实际处方经验也非常积极[15] 未来展望 - COPD市场潜力巨大，美国有约30万名2型COPD患者，而G7国家总共约55万名患者，这为Dupixent的推出提供了强大机会[18] - Dupixent有望成为COPD领域的首个获批生物制剂，市场上对于这一产品的期待很高[19] - linvoseltamab具有出色的特点，如果与竞争对手以相同的价格和准入条件同时推出，将完全占据市场[35] 新产品和新技术研发 - Regeneron计划在肥胖领域进行研究，希望通过肌肉保护抗体来改善健康结果[41] - Regeneron将进行第二阶段研究，结合semaglutide和肌肉保护抗体，评估体重和脂肪减少情况[44] - Regeneron还有其他肥胖项目，包括leptin受体激动剂抗体和GPR75基因的研究[50] 市场扩张和并购 - 公司已经开始加快偿还与Sanofi的合作中的发展余额，截至2023年底，余额为23亿美元[30] - Regeneron不会盲目进行并购，会根据内部情况选择性地进行交易[54] - 未来可能考虑分红，特别是在发展平衡得到解决后[55]

TARRYTOWN, N.Y. and WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Achyuta Rajaram, 17, of Exeter, NH, won the top award in the Regeneron Science Talent Search (STS) 2024, America's oldest and most prestigious science and math competition for high school seniors. The competition, now in its 83rd year, has consistently identified young innovators who become tomorrow's STEM leaders. The 2024 finalists dem ...

Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA extended the approval of the cholesterol drug Praluent’s (alirocumab) label.The regulatory body approved the drug as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies to include pediatric patients aged eight and older with heterozygous familial hypercholesterolemia (HeFH).The approval is based on a phase III, randomized multi-center trial evaluating pediatric patients aged 8 to 17 with HeFH, who had LDL-C ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Barclays 26th Annual Global Healthcare Conference Transcript March 12, 2024 11:15 AM ET Executives Chris Fenimore - Chief Financial Officer Ryan Crowe - Vice President, Investor Relations Analysts Carter Gould - Barclays Carter Gould Great. All right. Good morning. And welcome to the Barclays Global Healthcare Conference. My name is Carter Gould covering large-cap biopharma here at Barclays. Welcome, everyone. I’m pleased to welcome Regeneron Pharmaceuticals to ...

业绩总结 - 公司在2024年的指导中，研发支出预计将同比增长约12%[15] - 公司的Sanofi合作利润率在2023年增加了约300个基点[33] 新产品和新技术研发 - 公司正在积极研究Dupixent的生命周期管理，包括对过敏领域的机会[36] - 公司正在进行旨在逆转IgE介导过敏的早期临床研究[40] - Zoller的新批准在某种程度上代表了公司所面临的机会，但存在行动风险[41] - 公司的生物学理念是通过Dupixent阻止IgG和IgG分类的产生，这在生物学上是有道理的[44] - Itepekimab可能与Dupilumab共同治疗类型2前吸烟者，两者在同一患者群体中的效果值得关注[55] 市场扩张和并购 - 公司与Sanofi的合作余额为23亿美元，计划在未来几年继续偿还[13] 其他新策略和有价值的信息 - IL-33项目是圣诺菲合作的一部分，会与Dupixent和KEVZARA一起计入利润和销售额[47] - Trevogrumab在肥胖研究中进入Phase 2阶段，预计2025年上半年或中期会有数据更新[64] - Regeneron对肥胖问题的研究是重要的，数据将决定未来战略方向，希望结果积极，将进一步推进肥胖研究[67] - Regeneron在肥胖研究中拥有自己的GLP-1项目，同时也考虑与其他合作伙伴合作，以寻求最佳策略[69]